Skip to main content

Table 2 Lifetime use of different NSAIDs and breast cancer risk according to duration, average frequency and pill-yearsa of use, the Sister Study (2003–2013)

From: Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer

 

Cases

HR (95 % CI)b

 

Cases

HR (95 % CI)b

 

Cases

HR (95 % CI)b

Aspirin

Duration of use, y

Frequency of use, per week

Pill-years of use, py

<5

1830

1. (Ref.)

No use

1483

1. (Ref.)

<0.75

1489

1. (Ref.)

5- < 10

132

0.83 (0.69–1.02)

<4

71

0.87 (0.68–1.13)

0.75- < 14

191

1.09 (0.94–1.28)

10- < 20

97

0.95 (0.76–1.19)

4- < 7

82

1.14 (0.9–1.43)

14- < 49

266

0.97 (0.85–1.11)

≥ 20

59

0.93 (0.70–1.24)

≥ 7

481

1.07 (0.95–1.21)

≥ 49

172

0.95 (0.81–1.12)

P c

 

0.386

P c

 

0.202

P c

 

0.593

Low dose aspirin

Duration of use, y

Frequency of use, per week

Pill-years of use, py

<1

1978

1. (Ref.)

No use

1708

1. (Ref.)

<0.75

1711

1. (Ref.)

1- < 5

90

0.86 (0.72–1.11)

<7

61

0.99 (0.76–1.29)

0.75- < 21

203

1.07 (0.92–1.24)

≥ 5

50

0.88 (0.65–1.2)

≥ 7

349

1.05 (0.91–1.2)

≥ 21

204

0.93 (0.8–1.08)

P c

 

0.240

P c

 

0.539

P c

 

0.541

Regular strength aspirin

Duration of use, y

Frequency of use, per week

Pill-years of use, py

<1

1965

1. (Ref.)

No use

1866

1. (Ref.)

<0.75

1870

1. (Ref.)

1- < 5

45

0.76 (0.55–1.06)

<7

94

0.99 (0.77–1.26)

0.75- < 21

92

0.98 (0.79–1.21)

≥ 5

108

0.98 (0.77–1.25)

≥ 7

156

1.12 (0.92–1.36)

≥ 21

156

1.03 (0.87–1.22)

P c

 

0.726

P c

 

0.590

P c

 

0.775

COXibs d

Duration of use, y

Frequency of use, per week

Pill-years of use, py

<1

1954

1. (Ref.)

No use

1901

1. (Ref.)

<0.75

1904

1. (Ref.)

1- < 5

134

1.06 (0.76–1.43)

<7

42

1.19 (0.82–1.72)

0.75- < 21

139

1.05 (0.88–1.25)

≥ 5

30

0.71 (0.46–1.09)

≥ 7

175

0.95 (0.73–1.24)

≥ 21

75

0.86 (0.68–1.09)

P c

 

0.205

P c

 

0.590

P c

 

0.431

Non-aspirin, non-COXib NSAIDs

Duration of use, y

Frequency of use, per week

Pill-years of use, py

<5

1845

1. (Ref.)

No use

1462

1. (Ref.)

No use

1470

1. (Ref.)

5- < 10

128

1.05 (0.86–1.28)

<4

156

1.04 (0.87–1.26)

<4

248

0.94 (0.85–1.11)

10- < 20

99

0.85 (0.7–1.06)

4- < 7

130

1.13 (0.93–1.37)

4- < 7

241

1.02 (0.89–1.17)

≥ 20

46

0.92 (0.68–1.25)

≥ 7

369

0.90 (0.79–1.02)

≥ 7

159

0.84 (0.71–0.99)

P c

 

0.260

P c

 

0.144

P c

 

0.130

  1. aOne pill-year is equivalent to taking 1 pill per week for 1 year
  2. bAdjusted for race/ethnicity (non-Hispanic white; black; Hispanic; or others), level of education (high school graduate or less; some colleges or associate degree; or college degree or higher), history of benign proliferative breast disease (fibrocystic/benign changes; fibroadenoma; proliferative changes; or ductal/lobular hyperplasia), number of 1st degree family members with breast cancer (1; 2; or ≥ 3), BMI (<18.5; 18.5–24.9; 25–29.9; 30–34.9; 35–39.9; or ≥ 40 kg/m2), age at 1st term birth (<24y; 24–29y; ≥ 30y; or nulliparous), time since the last mammogram (<1 year; 1- < 2 years; or ≥ 2 years) and menopause status at diagnosis; duration and frequency of use were mutually adjusted
  3. cP for linear trend
  4. dSelective COX-2 inhibitors such as celecoxib, rofecoxib or valdecoxib
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us